Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a proof-of-concept study of tezosentan infusion in pulmonary arterial hypertension
2009-012450-20Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tezosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in pulmonary vascular resistance at 30 minutes. Started Sep 2009; status: completed.
02
Drugs
tezosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-012450-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012450-20.